Measurement of activated protein C resistance during menstrual cycle in women with and without the Leiden mutation

Thrombosis and Haemostasis

Volumn 85, Issue 4, 2001, Pages 614-618

  Wramsby, M L ^a   Bremme, K ^a   Blomback M ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

APC ratio; Menstrual cycle

Indexed keywords

ACTIVATED PROTEIN C; BLOOD CLOTTING FACTOR 5 LEIDEN; ESTRADIOL;

ACTIVATED PROTEIN C RESISTANCE; ADULT; ARTICLE; ASSAY; BIOMEDICAL TECHNOLOGY ASSESSMENT; BLOOD SAMPLING; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC PROCEDURE; DISEASE CARRIER; ESTRADIOL BLOOD LEVEL; FEMALE; GENE MUTATION; GENETIC ASSOCIATION; HUMAN; HUMAN EXPERIMENT; LUTEAL PHASE; MENSTRUAL CYCLE; NORMAL HUMAN; OVULATION; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL;

EID: 0035071453     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1615642     Document Type: Article

References (20)

1. Mutation in blood coagulation factor V associated with resistance to activated protein C
2. Development of resistance to activated protein C during pregnancy
3. Variability of the response to activated protein C during normal pregnancy
4. Activated protein C resistance in normal pregnancy
5. Response to activated protein C during normal menstrual cycle and ovarian stimulation
6. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: Prediction of a cofactor to activated protein C
7. Thrombotic risk factors and oral contraception
8. A rapid screening method for the factor V Arg506-Gln mutation
9. Influence of plasma platelets on activated protein C resistance assay
10. Laboratory diagnosis of APC resistance: A critical evaluation of the test and the development of diagnostic criteria
11. Modified test for activated protein C resistance
12. Modified APC resistance assay for patients on oral anticoagulants
13. A reduced sensitivity for protein C in the absence of Factor V Leiden increases the risk of venous thrombosis
14. Pseudohomozygosity for activated protein C resistance is a risk factor for venous thrombosis
15. A factor V genetic component differing from factor V R506Q contributes to the activated protein C resistance phenotype
16. Factor V Cambridge: A new mutation (Arg306→Thr) associated with resistance to activated protein C
17. The prevalence of factor V Arg306→Thr (factor V Cambridge) and factor V Arg306→Gly mutations in different human populations
18. A comparative study of the hemostatic effects of two monophasic oral contraceptives containing 30 mg ethinylestradiol and either 2 mg chlormadinone acetate or 150 mg desogestrel
19. Low-dose oral contraceptives and acquired resistance to activated protein C: A randomised cross-over study
20. Prediction of changes in levels of haemostatic variables during menstrual cycle and ovarian hyperstimulation